nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-89DCC77D·Framework v5.9·Pipeline v0.4·Evaluated 08 Oct 2026·OECD: 3.3 Neurology·Subfield: Physiology·Basis: Full text·Type: Laboratory experiment

Dysregulation of complement at the synapse in P301S mice and human tauopathies.

Nimmo et al.Nimmo, Daskoulidou, Van Pottelberge et al.·2026·Acta neuropathologica communications·10.1186/s40478-026-02347-2 ↗

Primary claim

These findings demonstrate that complement dysregulation occurs in areas of tau pathology and may contribute to synapse loss in tauopathies.

Tentative · causal contribution is inferred from associative mouse and post-mortem comparisons without a complement intervention
In brief

Age-resolved mouse and human data extend synaptic complement research through CSMD1, but statistical incoherence prevents confidence in the reported mechanism.

ReliabilityCaveats4 of 4 checks completeRead the 3 entries ↓
Fragile — the claim's weakest requirement is that it works through the path described. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.
Abstract

Synapse loss is the best correlate of cognitive decline in neurodegenerative diseases (NDDs). In Alzheimer's disease complement dysregulation, triggered by amyloid-β accumulation, plays a major role in synapse loss, but its contribution in other NDDs where amyloid is absent, most notably tauopathies, is elusive. Aggregation of tau is a prominent co-pathology in many NDDs and is characteristic of classical tauopathies in which amyloid pathology is lacking. Here we explore the effect of tau accumulation on complement dysregulation and its contribution to neuronal damage and synapse loss in a mouse tauopathy model harbouring the familial P301S tau mutation and post-mortem brain samples from human tauopathies. Complement gene and protein expression were analysed in P301S mice at 2, 4 and 6 M of age. Complement dysregulation was evident from qPCR analysis showing increased classical pathway (C4, C2), and complement receptor (C3ar1, Cd11b, Cd11c) gene expression in P301S mice compared to wildtype (WT). C1q protein levels were markedly increased in brain homogenates from P301S mice compared to WT, accompanied by C1q deposition on tau aggregates. Synapse loss was evident for both excitatory and inhibitory synapses and was accompanied by an increased percentage of C1q positive excitatory synapses, unaffected by proximity to tau aggregates. The classic pathway regulator CSMD1 was present on synapses and decreased on C1q positive synapses in P301S mice, implying a loss of protection from complement attack. Observations in human tauopathy brains demonstrated decreased CSMD1-labelled excitatory synapses, consistent with findings in P301S mice. These findings demonstrate that complement dysregulation occurs in areas of tau pathology and may contribute to synapse loss in tauopathies.

Key Claims

Primary finding · Tentative

These findings demonstrate that complement dysregulation occurs in areas of tau pathology and may contribute to synapse loss in tauopathies.

Fragile — the claim's weakest requirement is that it works through the path described. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.

causal contribution is inferred from associative mouse and post-mortem comparisons without a complement intervention

Abstract, final sentence; Conclusion
Quote verified
Secondary · Supported

C1q protein levels were markedly increased in brain homogenates from P301S mice compared to WT, accompanied by C1q deposition on tau aggregates.

large directional differences are reported, although incompatible ANOVA details reduce confidence in exact inference

Abstract; Results, Figs. 3–4
Quote verified
Secondary · Tentative

Synapse loss was evident for both excitatory and inhibitory synapses and was accompanied by an increased percentage of C1q positive excitatory synapses, unaffected by proximity to tau aggregates.

Fig. 6 reports fewer C1q-positive synapses around tau-positive neurons, contradicting the proximity wording

Abstract; Results, Figs. 5–6
Quote verified
Secondary · Tentative

The classic pathway regulator CSMD1 was present on synapses and decreased on C1q positive synapses in P301S mice, implying a loss of protection from complement attack.

CSMD1 differences are associative and absent at six months, with no functional perturbation of protection

Abstract; Results, Fig. 7
Quote verified
Secondary · Supported

in GGT cases there was a significant reduction in the percentage of total CSMD1 labelled synapses ... compared to healthy controls.

the reported direction is GGT-specific and rests on four heterogeneous post-mortem cases

Results, CSMD1 positive synapses are decreased in human tauopathies; Fig. 8
Quote verified

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#methodological rigour

Age-resolved mouse disease series

Complement transcripts, proteins, synaptic markers, and tau pathology are examined at 2, 4, and 6 months, covering the model's reported progression window.

↳ Methods, Animals; Results, Figs. 1–7

#contribution

CSMD1 adds a distinct angle

The study assesses a classical-pathway regulator at synapses in P301S mice and extends that measurement to CBD and GGT tissue, providing an incremental addition to prior C1q-focused work.

↳ Results, Figs. 7–8; Discussion, CSMD1 paragraphs

#positioning

Relevant prior studies are engaged

The article discusses earlier P301S complement-expression findings and C1q/C3 knockout studies, distinguishing the present descriptive work from existing functional evidence.

↳ Introduction, paragraph 2; Discussion, paragraphs 1 and 5

Limitations

#methodological rigour

Central statistics are internally inconsistent

Fig. 3 reports incompatible F and p values and anomalous factor degrees of freedom; Fig. 4 gives two correlation coefficients, and Fig. 2 conflicts with the Results on Cd11b timing. These defects require correction before the quantitative findings can be relied upon.

↳ Results and legends for Figs. 2–4

#reporting

Conclusions exceed associative evidence

The study does not manipulate complement or CSMD1, yet the Conclusion attributes resultant synapse loss to classical-pathway dysregulation in mice and humans. Fig. 8 reports no significant human synapse-density difference.

↳ Results, Fig. 8; Conclusion

#methodological rigour

Human validation is narrow and heterogeneous

The post-mortem groups are small and contain multiple co-pathologies, while the CSMD1 difference is significant only in GGT and is measured on total Bassoon-positive synapses rather than excitatory synapses.

↳ Methods, Human brain tissue; Table 1; Results and Fig. 8

Does this match your read? Add your assessment ↓

Nabu Commentary

The age-resolved mouse design and synaptic CSMD1 measurements provide a real but incremental addition to established complement work in P301S mice. The principal score constraint is quantitative coherence: Fig. 3 contains an incompatible F/p pairing and anomalous degrees of freedom, while Figs. 2 and 4 contain additional internal conflicts. The Abstract and Conclusion also overgeneralise the spatial and human findings, because Fig. 6 reports fewer C1q-positive synapses near tau-positive neurons and Fig. 8 shows neither human synapse loss nor a CBD CSMD1 effect. The study is therefore best treated as hypothesis-generating pending statistical correction and direct complement or CSMD1 perturbation.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
2.6±0.2

Contribution
3.0

The study adds age-resolved complement measurements and synaptic CSMD1 observations to an already established P301S complement literature. The advance is incremental because prior work had reported complement upregulation and knockout-associated protection, while the human extension is significant only for GGT.

Introduction, paragraphs 2–3; Results, Figs. 2–8

Whether complement directly causes synaptic dysfunction and loss is uncertain

Methodological Rigour
2.0

Per-mouse summaries, age-matched WT groups, both sexes, sourced reagents, and defined image-analysis thresholds support the design, but blinding and randomisation are unreported. Incompatible Fig. 3 statistics, uncertainty around the correlation unit, uncontrolled human heterogeneity, and causal interpretation of associative results substantially undermine execution.

Methods, Animals, Image analysis, and Statistics; Fig. 3 legend; Fig. 4f; Conclusion

may be attributed to complement classical pathway dysregulation

Reporting
2.8

The gene-to-protein-to-synapse-to-human sequence is easy to follow. Central wording is nevertheless misleading where the Abstract conflicts with Fig. 6 and characterises human CSMD1 measurements as excitatory-synapse findings despite Fig. 8 using total Bassoon-positive synapses.

Abstract; Results and Fig. 6; Results and Fig. 8; Conclusion

unaffected by proximity to tau aggregates

Positioning
3.3

The paper engages prior P301S C1q/C3 knockout studies and acknowledges that post-mortem tissue represents advanced disease. It does not fully trace model limitations, human co-pathologies, the null human synapse-density result, or the observational design through to the conclusion.

Introduction, paragraph 2; Discussion, final paragraph; Table 1; Conclusion

Post-mortem samples from human tauopathy cases inevitably represent advanced disease stages

Reliability

Caveats4 of 4 checks


Results checkNoted
  • C1q protein levels were markedly increased in brain homogenates from P301S mice compared to WT, accompanied by C1q deposition on tau aggregates: "A correlation analysis comparing neuronal levels of aggregated tau and C1q staining by Pearson analysis showed a significant positive correlation (r = 0.31, p < 0.0001; Fig. 4f)." (Results, C1q is deposited on neurons with tau aggregates) vs "Pearson correlation analysis of the mean fluorescent intensity of tau and C1q on neurons showed significant positive correlation (r = 0.24, p < 0.0001)." (Fig. 4 legend). The same tau–C1q correlation is reported as 0.31 and 0.24; both are positive, but neither can be selected as correct from the supplied text. → Effect on result unclear
  • Synapse loss was evident for both excitatory and inhibitory synapses and was accompanied by an increased percentage of C1q positive excitatory synapses, unaffected by proximity to tau aggregates: "Synapse loss was evident for both excitatory and inhibitory synapses and was accompanied by an increased percentage of C1q positive excitatory synapses, unaffected by proximity to tau aggregates." (Abstract) vs "the percentage of C1q-positive synapses was ~ 20–30% lower around tau-positive neurons compared to tau-negative (NeuN-stained) neurons" (Results, Loss of excitatory and inhibitory synapses). The Abstract's unqualified absence of a proximity effect conflicts with the reported approximately 20–30% lower C1q-positive fraction around tau-positive versus tau-negative neurons, although this comparison does not itself establish a distance gradient. → Not supported by the paper's own data
  • in GGT cases there was a significant reduction in the percentage of total CSMD1 labelled synapses ... compared to healthy controls: "tissue from two primary tauopathy disease subtypes, CBD (5 cases) and GGT (4 cases), were selected and compared to healthy controls (6 donors)" (Results, CSMD1 positive synapses are decreased in human tauopathies) vs "Brain sections from corticobasal degeneration (CBD, n = 5) and Globular glial tauopathy (GGT, n = 4) cases were compared to healthy control (n = 5)." (Fig. 8 legend). The Results specify six controls while Methods and Fig. 8 specify five, so the analyzed control count and any resulting change in significance cannot be established. → Effect on result unclear
  • These findings demonstrate that complement dysregulation occurs in areas of tau pathology and may contribute to synapse loss in tauopathies: "We demonstrate that synaptic loss in both P301S mice and human tauopathy brain may be attributed to complement classical pathway dysregulation at the synapse, particularly in the proximity of tau pathology." (Conclusion) vs "In contrast to mouse brain, there was no significant difference in synaptic density; however, a non-significant trend towards decreased excitatory synapses was observed in GGT compared to control cases" (Results, CSMD1 positive synapses are decreased in human tauopathies). The Conclusion presents human synaptic loss as demonstrated, whereas the human Results explicitly report no significant synaptic-density difference and only a nonsignificant excitatory-synapse trend. → Not supported by the paper's own data
Reporting and transparencyNoted

The supplied text leaves ANOVA factor labels and analysis sizes unresolved, does not clearly identify the correlation's analysis unit or explain the Fig. 6 sample-size range, and asserts an unpresented sex comparison.

Ethics approval: declared

Reference IntegrityNoted

27 references in manuscript 27 of 27 checkable references found in an index the reference list may be incompletely parsed; counts are indicative

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Neurological · Alzheimer's disease and other dementias
Type of advanceEmpirical
Route to useSuggested
AdvanceAdvances
BeneficiariesLarge
CitationsToo early
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessControlled
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The mechanism was pinned down in a controlled tauopathy mouse model, while the human post-mortem data are small, observational and only partially replicate the mouse findings.

From the paper
“anti-complement drugs, already proposed for treatment of AD, may also have a role in therapy of tauopathies”

The conclusion names a real-world therapeutic use of the findings but does not specify who would develop or apply such drugs.

Pathway

Drug developers and neurologists could test anti-complement therapies in tauopathy patients to prevent complement-mediated synapse loss and cognitive decline.

Barrier

Causality is unproven: no complement intervention was tested here, and human validation came from few post-mortem cases with mostly non-significant synapse differences.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. Comparing amyloid immunotherapy with cholinesterase inhibitors for Alzheimer's disease

    2026 · Neurology and psychiatry

    Evidence Score
    3.4±0.2
    Reliability
    No concerns
  2. Divergent toxicity mechanisms of amyloid-beta aggregates arising from a single aggregation reaction

    2026 · Basic medicine

    Primary claim

    aggregates enriched during the growth phase downregulated homeostatic microglial markers and induced TLR4-mediated microglial activation, cytokine production, and complement activation, leading to synaptic engulfment and severe disruption of neuronal activity

    Tentative
    Evidence Score
    2.8±0.2
    Reliability
    Caveats
  3. A timeline of tau-mediated synaptotoxicity

    2026 · Basic medicine

    Primary claim

    even brief tau oligomer exposure induces lasting bipartite synapse dysfunction and presenting a timeline of progressive pre- and post-synaptic degeneration.

    Tentative
    Evidence Score
    3.2±0.2
    Reliability
    No concerns

How the rubric works →